BIOMAT Database Logo BIOMAT Database Logo

[Results of 6 months, therapy of familial hypercholesterolemia (hyperlipoproteinemia type II) with colestipol]. 1980

M Kuŝić, and M Gavrilović, and M Mihajloviĉ, and B Boŝković

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011073 Polyamines Amine compounds that consist of carbon chains or rings containing two or more primary amino groups. Polyamine
D002784 Cholesterol The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. Epicholesterol
D003084 Colestipol Highly crosslinked and insoluble basic anion exchange resin used as anticholesteremic. It may also may reduce triglyceride levels. Colestid,Colestipol HCl,Colestipol Hydrochloride,U-26,597 A,HCl, Colestipol,Hydrochloride, Colestipol,U 26,597 A,U26,597 A
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006938 Hyperlipoproteinemia Type II A group of familial disorders characterized by elevated circulating cholesterol contained in either LOW-DENSITY LIPOPROTEINS alone or also in VERY-LOW-DENSITY LIPOPROTEINS (pre-beta lipoproteins). Hyperbetalipoproteinemia,Hypercholesterolemia, Essential,Hypercholesterolemia, Familial,Apolipoprotein B-100, Familial Defective,Apolipoprotein B-100, Familial Ligand-Defective,Familial Combined Hyperlipoproteinemia,Hyper-Low Density Lipoproteinemia,Hyper-Low-Density-Lipoproteinemia,Hyper-beta-Lipoproteinemia,Hypercholesterolemia, Autosomal Dominant,Hypercholesterolemia, Autosomal Dominant, Type B,Hypercholesterolemic Xanthomatosis, Familial,Hyperlipoproteinemia Type 2,Hyperlipoproteinemia Type IIa,Hyperlipoproteinemia Type IIb,Hyperlipoproteinemia, Type II,Hyperlipoproteinemia, Type IIa,LDL Receptor Disorder,Apolipoprotein B 100, Familial Defective,Apolipoprotein B 100, Familial Ligand Defective,Autosomal Dominant Hypercholesterolemia,Autosomal Dominant Hypercholesterolemias,Combined Hyperlipoproteinemia, Familial,Combined Hyperlipoproteinemias, Familial,Density Lipoproteinemia, Hyper-Low,Density Lipoproteinemias, Hyper-Low,Disorder, LDL Receptor,Disorders, LDL Receptor,Dominant Hypercholesterolemia, Autosomal,Dominant Hypercholesterolemias, Autosomal,Essential Hypercholesterolemia,Essential Hypercholesterolemias,Familial Combined Hyperlipoproteinemias,Familial Hypercholesterolemia,Familial Hypercholesterolemias,Familial Hypercholesterolemic Xanthomatoses,Familial Hypercholesterolemic Xanthomatosis,Hyper Low Density Lipoproteinemia,Hyper beta Lipoproteinemia,Hyper-Low Density Lipoproteinemias,Hyper-Low-Density-Lipoproteinemias,Hyper-beta-Lipoproteinemias,Hyperbetalipoproteinemias,Hypercholesterolemias, Autosomal Dominant,Hypercholesterolemias, Essential,Hypercholesterolemias, Familial,Hypercholesterolemic Xanthomatoses, Familial,Hyperlipoproteinemia Type 2s,Hyperlipoproteinemia Type IIas,Hyperlipoproteinemia Type IIbs,Hyperlipoproteinemia Type IIs,Hyperlipoproteinemia, Familial Combined,Hyperlipoproteinemias, Familial Combined,Hyperlipoproteinemias, Type II,Hyperlipoproteinemias, Type IIa,LDL Receptor Disorders,Lipoproteinemia, Hyper-Low Density,Lipoproteinemias, Hyper-Low Density,Receptor Disorder, LDL,Receptor Disorders, LDL,Type 2, Hyperlipoproteinemia,Type II Hyperlipoproteinemia,Type II Hyperlipoproteinemias,Type IIa Hyperlipoproteinemia,Type IIa Hyperlipoproteinemias,Xanthomatoses, Familial Hypercholesterolemic,Xanthomatosis, Familial Hypercholesterolemic
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

M Kuŝić, and M Gavrilović, and M Mihajloviĉ, and B Boŝković
Results of colestipol therapy in Type II hyperlipoproteinemia.
January 1976, Atherosclerosis,
M Kuŝić, and M Gavrilović, and M Mihajloviĉ, and B Boŝković
Pediatric familial type II hyperlipoproteinemia: therapy with diet and colestipol resin.
January 1976, Pediatrics,
M Kuŝić, and M Gavrilović, and M Mihajloviĉ, and B Boŝković
Colestipol in familial type II hyperlipoproteinemia: a three-year trial.
September 1976, Clinical pharmacology and therapeutics,
M Kuŝić, and M Gavrilović, and M Mihajloviĉ, and B Boŝković
Colestipol and cholestyramine resin. Comparative effects in familial type II hyperlipoproteinemia.
November 1972, JAMA,
M Kuŝić, and M Gavrilović, and M Mihajloviĉ, and B Boŝković
[Combined therapy of hyperlipoproteinemia. Colestipol and gemfibrozil in the treatment of heterozygous familial hypercholesterolemia].
March 1992, Casopis lekaru ceskych,
M Kuŝić, and M Gavrilović, and M Mihajloviĉ, and B Boŝković
Current treatment of type II familial hyperlipoproteinemia (essential familial hypercholesterolemia).
January 1968, University of Michigan Medical Center journal,
M Kuŝić, and M Gavrilović, and M Mihajloviĉ, and B Boŝković
Migratory polyarthritis in familial hypercholesterolemia (type II hyperlipoproteinemia).
June 1968, Arthritis and rheumatism,
M Kuŝić, and M Gavrilović, and M Mihajloviĉ, and B Boŝković
[Diagnosis and therapy of familial hyper- -lipoproteinemia (familial hypercholesterolemia or familial hyperlipoproteinemia of type II)].
November 1971, Recenti progressi in medicina,
M Kuŝić, and M Gavrilović, and M Mihajloviĉ, and B Boŝković
[Type II hyperlipoproteinemia: treatment with colestipol and procetophen].
May 1978, La Nouvelle presse medicale,
M Kuŝić, and M Gavrilović, and M Mihajloviĉ, and B Boŝković
[Treatment of familial hypercholesterolemia - hyperlipoproteinemia type II with anion exchange resins].
January 1981, Vojnosanitetski pregled,
Copied contents to your clipboard!